Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Partyka

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Journal of Medicinal Chemistry|February 1, 1980
Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanesR T Standridge, H G Howell, H A Tilson, et al.
Journal of Immunology Research|August 11, 2020
Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia PatientsL Karabon, A Partyka, L Ciszak, et al.
Biology Open|December 6, 2012
ABT-737 synergizes with Bortezomib to kill melanoma cellsSteven N Reuland, Nathaniel B Goldstein, Katie A Partyka, et al.
The Journal of Investigative Dermatology|November 30, 2012
MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD)Steven N Reuland, Shilo M Smith, Lynne T Bemis, et al.
Journal of Medicinal Chemistry|May 1, 1982
Structural modifications of anguidin and antitumor activities of its analoguesT Kaneko, H Schmitz, J M Essery, et al.
Oncotarget|November 10, 2016
Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatmentsNabanita Mukherjee, Adam Almeida, Katie A Partyka, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Journal of Medicinal Chemistry|February 1, 1980
Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanesR T Standridge, H G Howell, H A Tilson, et al.
Journal of Immunology Research|August 11, 2020
Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia PatientsL Karabon, A Partyka, L Ciszak, et al.
Biology Open|December 6, 2012
ABT-737 synergizes with Bortezomib to kill melanoma cellsSteven N Reuland, Nathaniel B Goldstein, Katie A Partyka, et al.
The Journal of Investigative Dermatology|November 30, 2012
MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD)Steven N Reuland, Shilo M Smith, Lynne T Bemis, et al.
Journal of Medicinal Chemistry|May 1, 1982
Structural modifications of anguidin and antitumor activities of its analoguesT Kaneko, H Schmitz, J M Essery, et al.
Oncotarget|November 10, 2016
Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatmentsNabanita Mukherjee, Adam Almeida, Katie A Partyka, et al.
Pageof 3